Overview

• In nearly 800 patients across 214 sites with uncontrolled or resistant hypertension, baxdrostat added to standard therapy outperformed placebo at 12 weeks.
• About 40% of participants on baxdrostat reached guideline blood pressure targets compared with under 20% on placebo.
• Safety findings were generally manageable, with hyperkalaemia reported in about 1.1% of treated patients and no unexpected signals.
• Blood‑pressure reductions persisted to 32 weeks in follow‑up, while experts call for longer‑term outcomes data and clearer criteria to identify responders.
• Results were presented at the ESC Congress and published in NEJM, as AstraZeneca says it will file before year‑end with potential approvals targeted in 2026.